| Autor: |
Ni-Chung Lee, Yin-Hsiu Chien, Chung-Hsing Wang, Siew-Lee Wong, Steven Shinn-Forng Peng, Fuu-Jen Tsai, Wuh-Liang Hwu |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Molecular Genetics and Metabolism Reports, Vol 31, Iss , Pp 100867- (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2214-4269 |
| DOI: |
10.1016/j.ymgmr.2022.100867 |
| Popis: |
Patients with Gaucher disease type 3 (GD3), especially those with GBA p.L444P homozygous mutation, often suffer from complications including lymphadenopathy even under regular enzyme replacement therapy (ERT). In order to improve their outcome, we administrated eliglustat, a substrate reduction therapy (SRT), in combination with ERT to four patients, age ranged 9–18 years, for two years. The results revealed that patients' plasma glucosylsphingosine (lyso-GL1) level and chitotriosidase activity both decreased after adding eliglustat. In three patients who completed follow-up MRI scanning, sizes of lymph nodes all decreased. No severe adverse events were attributed to eliglustat. Therefore, our data suggest that a combined SRT and ERT treatment may improve the ERT-resistant symptoms in patients with GD3. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
